AUCATZYL Patent Timeline Locked: Speak Up by April 2026
Published Date: 2/13/2026
Notice
Summary
The FDA has officially set the review period for AUCATZYL, a human biological product, which helps decide how long its patent can be extended. This affects the company behind AUCATZYL and anyone tracking patent timelines, with key deadlines for public comments and petitions coming up in April and August 2026. If you think the dates are wrong or want to challenge the applicant’s diligence, now’s the time to speak up!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
FDA sets AUCATZYL review period
The FDA determined the regulatory review period for AUCATZYL is 1,671 days total — 1,313 days in the testing phase and 358 days in the approval phase. Those periods are tied to the dates April 14, 2020 (testing start), November 17, 2023 (BLA submission), and November 8, 2024 (approval).
Applicant seeks 496 or 705 days extension
In its patent-extension application, the applicant seeks either 496 days or 705 days of patent term extension, while FDA's determination establishes a maximum potential period; the USPTO will apply statutory limits when calculating the actual extension amount.
Deadlines to challenge dates and diligence
If you believe any published dates are wrong, you must ask for a redetermination by April 14, 2026. If you want FDA to decide whether the applicant acted with due diligence during the review period, you must file a petition by August 12, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
Previous / Next Documents
Previous: 2026-02971 — Determination of Regulatory Review Period for Purposes of Patent Extension; ATTRUBY
The FDA has set the official review period for ATTRUBY, a human drug, so its patent holder can apply for extra patent time. This affects the drug company by potentially extending their exclusive rights, giving them more time to make money before generics arrive. People can challenge the dates or the company’s effort by mid-2026, so keep an eye on those deadlines!
Next: 2026-02973 — Determination of Regulatory Review Period for Purposes of Patent Extension; CRENESSITY
The FDA has officially set the review period for CRENESSITY, a new drug, so its patent can be extended. This helps the drug maker get extra time to protect their invention, which could affect when generic versions hit the market. If anyone thinks the dates are wrong or wants to challenge the drug maker’s speed during review, they have until April 14 or August 12, 2026, to speak up.